LT and SOX9 expression are associated with gene sets that distinguish Merkel cell polyomavirus-positive and -negative Merkel cell carcinoma.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
23 Jan 2024
Historique:
received: 12 07 2023
revised: 13 01 2024
accepted: 19 01 2024
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: aheadofprint

Résumé

Merkel cell carcinoma (MCC) is an aggressive malignant neuroendocrine tumour. There are two subsets of MCC, one related to Merkel cell polyomavirus (MCPyV) and the other to ultraviolet (UV) radiation. MCPyV-positive and MCPyV-negative MCCs have been considered to be different tumours, since the former type harbours few DNA mutations and is not related to UV radiation, and the latter usually arises in sun-exposed areas and may be found in conjunction with other keratinocytic tumours, mostly squamous cell carcinomas. Two viral oncoproteins, large T antigen (LT, coded by MCPyV_gp3) and small T antigen (sT, coded by MCPyV_gp4), promote different carcinogenic pathways. We hypothesized that the biological behaviours of MCPyV-positive and MCPyV-negative MCCs are different. We aimed to determine which genes are differentially expressed in MCPyV-positive and MCPyV-negative MCC, to describe the mutational burden and the most frequently mutated genes in the two MCC types, and to identify the clinical and molecular factors that may be related to patient survival. Ninety-two cases with a diagnosis of MCC were identified from the medical databases of the participating centres.To study gene expression, a customized panel of 172 genes was developed. Gene expression profiling was performed with nCounter Technology (NanoString Technologies, Seattle, WA, USA).For mutational studies, a customized panel of 26 genes was designed. Somatic single nucleotide variants (SNVs) were identified following the best practices GATK workflow for somatic mutations. The expression of LT enabled the series to be divided into two groups, (LT-positive, n=55; LT-negative, n=37). Genes differentially expressed in LT-negative cases were related to epithelial differentiation, especially SOX9, or proliferation and cell cycle (MYC, CDK6), among others. Congruently, LT displayed lower expression in SOX9-positive cases, and differentially expressed genes in SOX9-positive cases were related to epithelial/squamous differentiation.In LT-positive cases, the mean SNV frequency was 4.3 per case, and 10 per case in LT-negative cases (p=0.03).The expression of SNAI1 (HR=1.046, 95% CI=1.007-1.086, p=0.021) and CDK6 (HR=1.049, 95% CI=1.020-1.080, p=0.001) were identified as risk factors in a multivariate survival analysis. Tumours with weak expression of LT tend to co-express genes related to squamous differentiation and cell cycle, and to have a higher mutational burden. These findings are congruent with those of earlier studies.

Sections du résumé

BACKGROUND BACKGROUND
Merkel cell carcinoma (MCC) is an aggressive malignant neuroendocrine tumour. There are two subsets of MCC, one related to Merkel cell polyomavirus (MCPyV) and the other to ultraviolet (UV) radiation. MCPyV-positive and MCPyV-negative MCCs have been considered to be different tumours, since the former type harbours few DNA mutations and is not related to UV radiation, and the latter usually arises in sun-exposed areas and may be found in conjunction with other keratinocytic tumours, mostly squamous cell carcinomas. Two viral oncoproteins, large T antigen (LT, coded by MCPyV_gp3) and small T antigen (sT, coded by MCPyV_gp4), promote different carcinogenic pathways.
OBJECTIVES OBJECTIVE
We hypothesized that the biological behaviours of MCPyV-positive and MCPyV-negative MCCs are different. We aimed to determine which genes are differentially expressed in MCPyV-positive and MCPyV-negative MCC, to describe the mutational burden and the most frequently mutated genes in the two MCC types, and to identify the clinical and molecular factors that may be related to patient survival.
METHODS METHODS
Ninety-two cases with a diagnosis of MCC were identified from the medical databases of the participating centres.To study gene expression, a customized panel of 172 genes was developed. Gene expression profiling was performed with nCounter Technology (NanoString Technologies, Seattle, WA, USA).For mutational studies, a customized panel of 26 genes was designed. Somatic single nucleotide variants (SNVs) were identified following the best practices GATK workflow for somatic mutations.
RESULTS RESULTS
The expression of LT enabled the series to be divided into two groups, (LT-positive, n=55; LT-negative, n=37). Genes differentially expressed in LT-negative cases were related to epithelial differentiation, especially SOX9, or proliferation and cell cycle (MYC, CDK6), among others. Congruently, LT displayed lower expression in SOX9-positive cases, and differentially expressed genes in SOX9-positive cases were related to epithelial/squamous differentiation.In LT-positive cases, the mean SNV frequency was 4.3 per case, and 10 per case in LT-negative cases (p=0.03).The expression of SNAI1 (HR=1.046, 95% CI=1.007-1.086, p=0.021) and CDK6 (HR=1.049, 95% CI=1.020-1.080, p=0.001) were identified as risk factors in a multivariate survival analysis.
CONCLUSIONS CONCLUSIONS
Tumours with weak expression of LT tend to co-express genes related to squamous differentiation and cell cycle, and to have a higher mutational burden. These findings are congruent with those of earlier studies.

Identifiants

pubmed: 38261397
pii: 7585479
doi: 10.1093/bjd/ljae033
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Juan Torre-Castro (J)

Department of Dermatology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.

Marta Rodríguez (M)

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.
Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Ruth Alonso-Alonso (R)

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.
Center for Biomedical Network on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

María Dolores Mendoza Cembranos (MD)

Department of Dermatology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.

Jesús Frutos Díaz-Alejo (J)

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.

Marcos Rebollo-González (M)

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.

Jennifer Borregón (J)

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.

Laura Nájera Botello (L)

Pathology Department, Hospital Universitario Puerta de Hierro, Universidad Autónoma, Madrid, Spain.

Ignacio Mahillo-Fernández (I)

Biostatistics and Epidemiology Unit, Hospital Universitario Fundación Jiménez Díaz, Fundación Instituto de Investigación Sanitaria, Madrid, Spain.

Mathab Samimi (M)

Department of Dermatology, Centre Hospitalier Universitaire Tours, Tours Cedex, France.

Thibault Kervarrec (T)

Department of Pathology, Centre Hospitalier Universitaire Tours, Tours Cedex, France.

Luis Requena (L)

Department of Dermatology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.

Miguel Ángel Piris (M)

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.

Classifications MeSH